Connect to share and comment

Novo Nordisk posts better-than-expected earnings

Agence France-PresseMay 1, 2013 03:45
Danish pharmaceutical group Novo Nordisk, the world's biggest producer of insulin for diabetes sufferers, on Wednesday topped analyst profit expectations for its first quarter of 2013 From January to March, the group posted a net profit of 5.982 billion Danish kroner (802 million euros), as it enjoyed strong sales of its diabetic drug Victoza and "modern insulins." Analysts polled by Dow Jones Newswires predicted 5.85 billion kroner in net profit.

European shares led lower by Novo Nordisk

February 11, 2013 13:00
LONDON, Feb 11 (Reuters) - European equities eased on Monday, continuing the previous week's retreat from multi-month peaks and dragged down by a sharp sell off in Novo Nordisk after its key drug suffered a regulatory approval set-back. The weakness in European equities was fairly broad with all but two sectors in the red. Energy and mining stocks were hit by falling commodity prices while continued political turbulence in Italy and Spain weighed on banks and on their national indexes.

Denmark faces Nokia moment as Novo weighs in at $100 bln

February 1, 2013 04:30
* Novo Nordisk biggest firm by market cap in the Nordics * Shares up almost 40 pct in 2012 on strong global insulin demand * Stock exchange changing key index to cap weighting at 20 pct By Mia Shanley and Shida Chayesteh COPENHAGEN, Feb 1 (Reuters) - Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.
Syndicate content